Cassava Sciences Inc vs First Trust Cloud Computing ETF — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while First Trust Cloud Computing ETF trades at $161.24. The key difference: First Trust Cloud Computing ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SKYY | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | — |
52-Week High | $4.64 | $161.09 |
52-Week Low | $0.87 | $104.16 |
Enterprise Value | -$34.93M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
First Trust Cloud Computing ETF (SKYY) trades at $163.00, up 1.38% with bullish technical signals from moving averages and ADX indicators. The ETF provides diversified exposure to cloud infrastructure, software, and AI companies, benefiting from secular trends in cloud migration and AI adoption. Recent news highlights strong institutional interest in technology ETFs and SKYY's positioning in the expanding AI ecosystem beyond semiconductors.
SKYY offers exposure to cloud computing growth drivers with technical momentum supporting near-term upside. Key risks include technology sector volatility and competitive pressures from global cloud initiatives. The ETF's diversified approach mitigates concentration risk while capturing broader technology transformation trends.
Trailing returns across standard periods
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →